FRANKFURT (Reuters) - AstraZeneca said combining its Forxiga type-2 diabetes drug with older medicine Bydureon was more effective at controlling blood sugar levels than treatment with either drug on ...

Just days after winning groundbreaking coverage for a key cancer med, AstraZeneca ($AZN) on Friday notched another win from England’s cost-effectiveness watchdogs ...

AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) look to be feeling good about the future of their diabetes drug Forxiga. The drugmakers have yanked the diabetes ...

The NHS has warned UK patients taking a commonly prescribed medication to seek urgent medical attention if they notice any of three specific symptoms. These can indicate serious complications due ...

AstraZeneca has gained access to millions of potential patients with chronic kidney disease (CKD) in Japan with its new indication for Forxiga. Forxiga's sales growth is set to continue -- it was also ...

AstraZeneca and Bristol-Myers Squibb are celebrating following the approval of their diabetes drug Forxiga in the European Union. AstraZeneca and Bristol-Myers Squibb are celebrating following the ...

The European Commission (EC) approved AstraZeneca (NASDAQ:AZN) Forxiga for expanded use to treat heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of ...

The EMA's approval of Forxiga for chronic kidney disease gives AstraZeneca access to millions of patients in the EU. Forxiga's efficacy and this massive potential market should help the label ...

(RTTNews) - British drug major AstraZeneca (AZN.L, AZN) announced Thursday that its Japan's Ministry of Health, Labour and Welfare has approved Forxiga (dapagliflozin), a sodium-glucose cotransporter ...

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble FRANKFURT (Reuters) - AstraZeneca said combining its Forxiga type-2 diabetes drug with older ...